Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro.
The combination of fluconazole with either ibuprofen, sodium salicylate, or propylparaben resulted in synergistic activity (fractional inhibitory index, < 0.5) against Candida albicans NCYC 620 in a microdilution checkerboard assay. Synergism between miconazole and ibuprofen was also demonstrated. In three or four clinical isolates of C. albicans from AIDS patients, the combination of fluconazole and ibuprofen was synergistic. Preparation of the inoculum and the growth conditions used were those recommended by the National Committee for Clinical Laboratory Standards for susceptibility testing. A visual estimation of total inhibition of growth and determination of an 80% reduction in the optical density at 492 nm compared with those for the control were taken as endpoints for the calculation of synergy, and a good correlation between both estimates was demonstrated.
Scott
E M
EM
School of Pharmacy, Queen's University of Belfast, Northern Ireland, United Kingdom.
Tariq
V N
VN
McCrory
R M
RM
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology; D003720:Densitometry; D004357:Drug Synergism; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010226:Parabens / Q000494:pharmacology*; D012980:Sodium Salicylate / Q000494:pharmacology*
D000935:Antifungal Agents; D010226:Parabens; D015725:Fluconazole; D012980:Sodium Salicylate; D007052:Ibuprofen; C006068:propylparaben